Exciting times in diabetes treatment: new drug class moves beyond glucose reduction
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Muthiah Vaduganathan, MD, MPH
Jurgen Floege MD
- ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
Deepak Bhatt, MD
James Januzzi, MD